Work

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase

Year: 2011

Type: article

Source: Leukemia Research

DOI: 10.1016/j.leukres.2011.07.011

Authors: Amir T. Fathi, Omotayo Arowojolu, Ian Swinnen, Takashi Sato, Trivikram Rajkhowa, Donald Small, Fredrik Marmsater, John E. Robinson, Stefan David Gross, Matthew Martinson, Shelley Allen, Nicholas C. Kallan, Mark Levis

Institutions: Harvard University, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Array BioPharma (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Society of Clinical Oncology, National Cancer Institute

Awards: SPORE University of Texas M. D. Anderson Cancer Center-Leukemia, Incorporating FLT3 inhibitors into AML treatment regimens, FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia, Molecular Targets for Cancer Detection and Treatment, Regional Oncology Research Center

OpenAlex ID: W2021619817

FWCI: 4.608

Cites: 57

Cited by: 57

Related to: 10